Pharma Industry
Industry: Email Alert RSS FeedMAP Pharma, AstraZeneca will develop asthma drug
Chain Drug Review, Jan 19, 2009
AstraZeneca PLC and MAP Pharmaceuticals have agreed to develop and commercialize the latter's pediatric asthma drug. MAP is working on unit-dose budesonide as a potential treatment for asthma in patients from 1 to 8 years old. AstraZeneca will make an up-front cash payment of $40 million to MAP.
Most RecentPharma Articles
Separately, AstraZeneca has submitted a supplemental new drug application for Nexium as a short-term treatment of gastroesophageal disease in infants.
- How to choose the right insurance carrier for your business
- Real Estate: Prepare your properties to weather what lies ahead
- Technology: Be prepared if part of your global supply chain goes missing
Most Recent Health Articles
Most Recent Health Publications
Most Popular Health Articles
- 50 home remedies that work: these safe, fast, and effective fixes will relieve what ails you - Cover Story
- Detox in 7 days: a detoux diet can help you shed up to 10 pounds and leave you feeling terrific. Our weeklong plan shows you how to lose the weight and keep it off - Cover story
- All about nightshades: explore the hidden hazards of your favorite food with macrobiotic nutritionist Lino Stanchich
- Treat sinusitis naturally: breath easy and relieve sinus pressure with these remedies - Quick Fixes and Long-Term Solutions
- La anemia falciforme - causas y tratamiento



